# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Oppenheimer analyst Hartaj Singh maintains Viracta Therapeutics (NASDAQ:VIRX) with a Outperform and lowers the price target ...
Viracta Therapeutics (NASDAQ:VIRX) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of ...
Shares of The Travelers Companies, Inc. (NYSE: TRV) fell sharply during Wednesday’s session following first-quarter earnings.
Oppenheimer analyst Hartaj Singh maintains Viracta Therapeutics (NASDAQ:VIRX) with a Outperform and maintains $13 price target.
HC Wainwright & Co. analyst Robert Burns reiterates Viracta Therapeutics (NASDAQ:VIRX) with a Buy and maintains $4 price...
Nanatinostat combined with valganciclovir shows promising results in treating relapsed or refractory EBV+ peripheral T-cell lym...